Sinopharm Group Co (Sinopharm Group Co) Short-Term Capital Lease Obligation : $252 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Short-Term Capital Lease Obligation?

Sinopharm Group Co's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $252 Mil.

Sinopharm Group Co's quarterly Short-Term Capital Lease Obligation declined from Jun. 2023 ($228 Mil) to Sep. 2023 ($0 Mil) but then increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($252 Mil).

Sinopharm Group Co's annual Short-Term Capital Lease Obligation declined from Dec. 2021 ($243 Mil) to Dec. 2022 ($235 Mil) but then increased from Dec. 2022 ($235 Mil) to Dec. 2023 ($252 Mil).

Sinopharm Group Co Short-Term Capital Lease Obligation Historical Data

The historical data trend for Sinopharm Group Co's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Short-Term Capital Lease Obligation Chart

Sinopharm Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

169.98

215.03

243.05

234.66

251.61

Sinopharm Group Co Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															234.66	227.77	-	251.61	-

Sinopharm Group Co Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Sinopharm Group Co Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co (Sinopharm Group Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SHTDY:USA 01099:Hong Kong X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (Sinopharm Group Co) Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan • 10-20-2014

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon • 10-18-2014

Arnold Van Den Berg Buys Prem Watsa's Fairfax India, 3 Other Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-31-2017

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 07-30-2020

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 01-25-2021